Enable JavaScript to visit this website.

NOW APPROVED

VYNDAQEL is the first and only treatment available for patients with ATTR-CM, indicated for the treatment of:

The cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular (CV) mortality and CV-related hospitalization

IMPORTANT SAFETY INFORMATION-abc